¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"adenosine diphosphate ribose cyclase"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • guanosine diphosphate =GDP
    ÀÌÀÎ»ê ±¸¾Æ³ë½Å.
  • guanosine diphosphate mannose =GDPM
    ÀÌÀλ길³ë½º±¸¾Æ³ë½Å.
  • ATP => adenosine triphosphate
    »ïÀÎ»ê¾Æµ¥³ë½Å
  • ATP=> adenosine triphosphate
    ¾Æµ¥³ë½Å »ïÀλê
  • ATP=£¾adenosine triphosphate
    ¾Æµ¥³ë½Å»ïÀλê.
  • adenosine
    ¾Æµ¥³ë½Å
  • adenosine 5-monophosphate
    ¾Æµ¥³ë½Å 5-ÀÏÀλ꿰
  • adenosine deaminase
    ¾Æµ¥³ë½Å, µð¾Æ¹Ì³ªÁ¦ <Å»¾Æ¹Ì³ëÈ¿¼Ò>.
  • adenosine deaminase
    ¾Æµ¥³ë½Åµ¥¾Æ¹Ì³ªÁ¦<--Å»¾Æ¹Ì³ëÈ¿¼Ò>
  • adenosine deaminase(ada)
    ¾Æµ¥³ë½Å µð¾Æ¹Ì³×À̽º
  • adenosine monophosphate
    ÀÏÀÎ»ê¾Æµ¥³ë½Å
  • adenosine monophosphate =AMP
    ÀÏÀÎ»ê¾Æµ¥³ë½Å.
  • adenosine triphosphatase
    ¾Æµ¥³ë½Å »ïÀλêÈ¿¼Ò
  • adenosine triphosphatase
    ¾Æµ¥³ë½Å Æ®¸®Æ÷½ºÆÄÅ×À̽º
  • adenosine triphosphate
    »ïÀÎ»ê¾Æµ¥³ë½Å
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • adenosine 5-monophosphate
    ¾Æµ¥³ë½Å 5-ÀÏÀλ꿰
  • adenosine deaminase
    ¾Æµ¥³ë½Åµ¥¾Æ¹Ì³ªÁ¦<--Å»¾Æ¹Ì³ëÈ¿¼Ò>
  • adenosine deaminase
    ¾Æµ¥³ë½Å, µð¾Æ¹Ì³ªÁ¦ <Å»¾Æ¹Ì³ëÈ¿¼Ò>.
  • adenosine deaminase(ada)
    ¾Æµ¥³ë½Å µð¾Æ¹Ì³×À̽º
  • adenosine monophosphate
    ÀÏÀÎ»ê¾Æµ¥³ë½Å
  • adenosine monophosphate =AMP
    ÀÏÀÎ»ê¾Æµ¥³ë½Å.
  • adenosine triphosphatase
    ¾Æµ¥³ë½Å »ïÀλêÈ¿¼Ò
  • adenosine triphosphatase
    ¾Æµ¥³ë½Å Æ®¸®Æ÷½ºÆÄÅ×À̽º
  • adenosine triphosphate
    »ïÀÎ»ê¾Æµ¥³ë½Å
  • adenosine triphosphate =ATP
    »ïÀÎ»ê ¾Æµ¥³ë½Å.
  • adenosine triphosphate(atp)
    ¾Æµ¥³ë½Å»ïÀλê(¡­ß²ìÝß«)
  • adenosine,deficiency
    °áÇÌÁõ(ÌÀù¹ñø)
  • cyclic AMP ; cyclic adenosine mono pho sph ate
    °í¸®¸ð¾ç AMP.¾à¸®È¯ ½Ä±¸¾Æ³ë½Å¸ð³ëÆ÷½ºÆäÀÌÆ®, »çÀÌŬ¸¯AMP, cAMP cyclic aclenosine 3 , 5 monophate
  • cyclic adenosine monophosphate
    °í¸® AMP
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • adenosine monophosphate
    ÀÏÀλê(ìéìÝß«)¾Æµ¥³ë½Å
  • adenosine triphosphatase
    ¾Æµ¥³ë½Å Æ®¸®Æ÷½ºÆÄÅ×À̽º
  • adenosine triphosphate
    »ïÀλê(ß²ìÝß« )¾Æµ¥³ë½Å
  • "adenosine-3',5'-cyclic monophosphate"
    ¾Æµ¥³ë½Å-3'-5'-°í¸® ÀÏ(ìé)Àλ꿰(×òß«ç¤)
  • adenosine-5'-phosphosulfate
    ¾Æµ¥³ë½Å-5'-ÀÎȲ»ê¿°(ìÝüÜß«ç¤)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CDP chondrodysplasia punctata; chronic destructive periodontitis; collagenase-digestible protein; contin...
Rib riboflavin; ribose
RP radial pulse; radiopharmaceutical; rapid processing [of film]; Raynaud phenomenon; reactive protein;...
R5P ribose-5-phosphate
RPI regional perfusion index; relative percentage index; reticulocyte production index, ribose 5-phospha...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PP-ribose-P 5'phosphoribosyl-l-pyrophosphate
ADPr ADP ribose
PARP B/poly-ADP ribose polymerase
cADPR Cyclic ADP ribose
R5P ribose 5'-phosphate
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
D-ribose reductase <enzyme> Ribose is converted to ribitol
Registry number: EC 1.1.-
(26 Jun 1999)
5-aminoimidazole ribose 5'-phosphate 5-amino-1-beta-d-ribofuranosylimidazole 5'-phosphate;an intermediate in the biosynthesis of purines.
Synonym: 5-aminoimidazole ribotide.
Acronym: AIR
(05 Mar 2000)
L-ribose reductase <enzyme> Nadph-linked E coli enzyme converts l-ribose to ribitol
Registry number: EC 1.1.1.-
(26 Jun 1999)
adenosine <biochemistry> A ribonucleotide which consists of the nitrogenous base adenine linked to the sugar ribose.
<drug> A cardiac drug used in terminating PSVT involving reentry pathways that include the AV node or Wolff-Parkinson-White syndrome. For atrial flutter, atrial fibrillation, atrial or ventricular tachycardias, adenosine may produce transient AV block that may help identify the rhythm.
Pharmacologic action: Endogenous purine nucleoside that depresses AV node and sinus node activity. Brief duration of action (1-2 min).
Dose: Rapid 6 mg IV bolus over 1-3 sec. May repeat at 12 mg IV bolus within 1-2 min Patients taking theophylline may require larger doses. Use a smaller dose with cardiac transplant patients.
Potential complications: Common but transient - flushing, dyspnea, chest pain, bradycardia, and ventricular ectopy. Theophylline (and caffeine) blocks adenosine's effects. Dipyridamole potentiates adenosine's effects. Use other agents to avoid these drug interactions.
(15 Mar 2000)
adenosine 3',5'-cyclic monophosphate An activator of phosphorylase kinase and an effector of other enzymes, formed in muscle from ATP by adenylate cyclase and broken down to 5'-AMP by a phosphodiesterase; sometimes referred to as the "second messenger." A related compound (2',3') is also known.
Synonym: cyclic adenylic acid, cyclic AMP, cyclic phosphate.
Acronym: cAMP
(05 Mar 2000)
adenosine 3',5'-cyclic phosphate phosphodiesterase <enzyme> An enzyme that catalyses the hydrolysis of adenosine 3',5'-cyclic phosphate forming 5'-AMP. A crucial step in the regulation of cellular adenosine 3',5'-cyclic phosphate levels. Inhibited by caffeine.
Synonym: cAMP phosphodiesterase.
(05 Mar 2000)
adenosine 3'-phosphate 3'-Adenylic acid.
See: adenylic acid.
(05 Mar 2000)
adenosine 3'-phosphate 5'-phosphosulfate 3'-phosphoadenosine 5'-phosphosulfate;an intermediate in the formation of urinary ethereal sulfates, notable for containing a "high energy" sulfate bond; the 3'-OH of adenosine is replaced by -OPO3H2, the 5'-OH by -OP(O2H)-OSO3H.
Synonym: active sulfate.
Acronym: PAPS
(05 Mar 2000)
adenosine-5'-(n-ethylcarboxamide) <chemical> A stable adenosine a1 and a2 receptor agonist. Experimentally, it inhibits camp and cgmp phosphodiesterase activity.
Pharmacological action: antineoplastic agent, vasodilator agents.
(12 Dec 1998)
adenosine 5'-phosphate 5'-Adenylic acid.
See: adenylic acid.
(05 Mar 2000)
adenosine 5'-phosphoramidate hydrolase <enzyme> Hydrolyzes nucleoside 5'-monophosphoramidates into nucleoside 5'-phosphates and ammonia
Registry number: EC 3.9.1.-
Synonym: ampn hydrolase, nucleoside monophosphoramidate hydrolase
(26 Jun 1999)
adenosine 5'-phosphosulfate An intermediate in the formation of PAPS (active sulfate).
Adenosine 5'-phosphosulfate kinase, the enzyme that catalyses the formation of active sulfate from adenosine 5'-phosphosulfate and ATP.
Acronym: APS
(05 Mar 2000)
adenosine 5'-phosphosulfate sulfotransferase <enzyme> Catalyses transfer of sulfo group of adenylylsulfate to a carrier organic thiol, forming carrier-bound thiosulfate and AMP
Registry number: EC 2.8.2.-
Synonym: apsstase, aps sulfotransferase, adenylylsulfate sulfotransferase
(26 Jun 1999)
adenosine 5'-triphosphate Adenosinepyrophosphate;adenosine with triphosphoric acid esterfied at its 5' position; immediate precursors of adenine nucleotides in RNA. The primary energy currency of a cell.
Synonym: adenosine triphosphate.
Acronym: ATP
(05 Mar 2000)
adenosine cyclic phosphate An activator of phosphorylase kinase and an effector of other enzymes, formed in muscle from ATP by adenylate cyclase and broken down to 5'-AMP by a phosphodiesterase; sometimes referred to as the "second messenger." A related compound (2',3') is also known.
Synonym: cyclic adenylic acid, cyclic AMP, cyclic phosphate.
Acronym: cAMP
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á